THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

The GLIOMATCH project has officially started in January 2024

Under the coordination of KU Leuven, the consortium of partners from diverse disciplines, including clinical experts, medical practitioners, data scientists, and health economists, will be working on pioneering personalised therapies for brain cancer patients.

More Posts

GLIOMATCH: Explained with Dr. Chiara Caprioli and Prof. Frederik De Smet

In this GLIOMATCH: Explained episode, Dr. Chiara Caprioli and Prof. Frederik De Smet from KU Leuven explain how new research has mapped the evolution of glioblastoma from diagnosis to recurrence, identified distinct tumour trajectories and established a framework that could support more personalised treatment decisions.

GLIOMATCH: Explained with Prof. Dr. Sandra Jacobs

In this GLIOMATCH: Explained episode, Prof. Dr. Sandra Jacobs introduces the paediatric clinical study, the participating centres and the challenges of working with archived samples from paediatric high-grade glioma patients.

GLIOMATCH marks World Brain Tumour Day at EU event on advancing brain cancer research

On World Brain Tumour Day 2026, GLIOMATCH participated in the European event “Advancing Brain Cancer Research: From policy action to scientific breakthroughs” at the European Parliament in Strasbourg. The event highlighted the urgent need to accelerate brain cancer research, strengthen European collaboration and turn scientific progress into improved care for patients.

GLIOMATCH: Explained with Prof. Dr. Steven De Vleeschouwer

In this GLIOMATCH: Explained episode, Prof. Dr. Steven De Vleeschouwer introduces the prospective clinical trials, the participating centres and the immunotherapy strategies being investigated to better understand patient response in brain tumours.